A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: Efficacy and safety results from the phase II, multi-center ANNIE study

BACKGROUND: Patients with platinum-resistant recurrent ovarian cancer (PROC) face poor prognosis and limited treatment options. Single-agent antiangiogenics and poly (ADP-ribose) polymerase (PARP) inhibitors both show some activities in platinum-resistant diseases. The ANNIE study aimed to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Guochen, Feng, Yanling, Li, Jing, Deng, Ting, Yin, Aijun, Yan, Lei, Zheng, Min, Xiong, Ying, Li, Jundong, Huang, Yongwen, Zhang, Chuyao, Huang, He, Wan, Ting, Huang, Qidan, Lin, An, Jiang, Jie, Kong, Beihua, Liu, Jihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793276/
https://www.ncbi.nlm.nih.gov/pubmed/36583171
http://dx.doi.org/10.1016/j.eclinm.2022.101767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793276/
https://www.ncbi.nlm.nih.gov/pubmed/36583171
http://dx.doi.org/10.1016/j.eclinm.2022.101767

Ejemplares similares